Summary of Significant Accounting Policies (Details Narrative) - USD ($) |
3 Months Ended | 6 Months Ended | 30 Months Ended | |||
---|---|---|---|---|---|---|
Jun. 30, 2015 |
Jun. 30, 2014 |
Jun. 30, 2015 |
Jun. 30, 2014 |
Jun. 30, 2015 |
Dec. 31, 2014 |
|
Patent costs | $ 84,745 | $ 88,055 | $ 212,226 | $ 155,799 | ||
Deferred setup and organization costs, amortization period | 180 months | |||||
Unrecognized tax benefits | 0 | $ 0 | $ 0 | $ 0 | ||
Theradex Systems, Inc [Member] | ||||||
Clinical costs charged to operations | $ 1,202,536 | |||||
Theradex Systems, Inc [Member] | ||||||
Clinical costs charged to operations | $ 150,107 | $ 93,581 | $ 500,708 | $ 173,233 | ||
Percentage of clinical research and development costs | 52.00% | 28.00% | 63.00% | 35.00% | ||
Theradex Systems, Inc [Member] | Phase 1 Clinical [Member] | ||||||
Total estimated clinical costs to be charged to operations | $ 2,615,000 | |||||
Percentage of clinical trial service | 60.00% | |||||
Percentage of clinical center laboratory cost | 40.00% |
X | ||||||||||
- Definition Clinical costs charged to operations. No definition available.
|
X | ||||||||||
- Definition Current estimated cost of clinical trial. No definition available.
|
X | ||||||||||
- Definition The amortization period for recovery of the deferred set-up and organization costs for Federal tax purposes. No definition available.
|
X | ||||||||||
- Definition Patent costs. No definition available.
|
X | ||||||||||
- Definition Percentage Of Clinical Center Laboratory Cost. No definition available.
|
X | ||||||||||
- Definition Percentage of clinical research and development costs. No definition available.
|
X | ||||||||||
- Definition Percentage Of Clinical Trial Service. No definition available.
|
X | ||||||||||
- Definition Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|